title: Imatinib plasma monitoring-guided dose modification for managing imatinib-related toxicities in gastrointestinal stromal tumor patients.
abstract: Imatinib, the first-line treatment in patients with advanced gastrointestinal stromal tumors (GIST), is generally well tolerated, although some patients have difficulty tolerating the standard dose of 400 mg/day. Adjusting imatinib dosage by plasma level monitoring may facilitate management of patients who experience intolerable toxicities due to overexposure to the drug. We present two cases of advanced GIST patients in whom we managed imatinib-related toxicities through dose modifications guided by imatinib plasma level monitoring. Imatinib blood level testing may be a promising approach for fine-tuning imatinib dosage for better tolerability and optimal clinical outcomes in patients with advanced GIST.
authors: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors: Shinkyo
authors: S
authors: Yoon
authors: Min-Hee
authors: MH
authors: Ryu
authors: Changhoon
authors: C
authors: Yoo
authors: Mo Youl
authors: MY
authors: Beck
authors: Baek-Yeol
authors: BY
authors: Ryoo
authors: Yoon-Koo
authors: YK
authors: Kang
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000097:blood / Q000627:therapeutic use*; D001549:Benzamides / Q000097:blood / Q000627:therapeutic use*; D016903:Drug Monitoring; D005091:Exons; D005770:Gastrointestinal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D046152:Gastrointestinal Stromal Tumors / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D009154:Mutation; D010879:Piperazines / Q000097:blood / Q000627:therapeutic use*; D049268:Positron-Emission Tomography; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics; D011743:Pyrimidines / Q000097:blood / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit
keywords: Dose-Modification; Gastrointestinal Stromal Tumors (GIST); Imatinib; Imatinib Plasma Monitoring
references: Oncology. 2009;76(5):326-32
references: 19307738
references: Jpn J Clin Oncol. 2006 Jan;36(1):17-24
references: 16418188
references: J Clin Oncol. 2010 Mar 20;28(9):1554-9
references: 20177019
references: Clin Pharmacokinet. 2005;44(9):879-94
references: 16122278
references: J Clin Oncol. 2009 Jul 1;27(19):3141-7
references: 19451435
references: Blood. 2008 Apr 15;111(8):4022-8
references: 18256322
references: Br J Cancer. 2008 May 20;98(10):1633-40
references: 18475296
references: Ann Surg. 1993 Jan;217(1):72-7
references: 8424704
references: Cancer Chemother Pharmacol. 2011 Jan;67 Suppl 1:S45-50
references: 21140148
references: Eur J Cancer. 2006 May;42(8):1093-103
references: 16624552
references: J Clin Oncol. 2010 Mar 1;28(7):1247-53
references: 20124181
references: N Engl J Med. 2002 Aug 15;347(7):472-80
references: 12181401
references: J Clin Oncol. 2004 Mar 1;22(5):935-42
references: 14990650